摘要
目的以利巴韦林单方为参照品 ,测定利巴韦林鱼腥草素钠复方粉针剂中主药成分利巴韦林在大鼠体内的药代动力学 ,并考察粉针剂中另一成分鱼腥草素钠对主药药代动力学的影响。方法采用 5 0 % (φ)高氯酸水溶液沉淀蛋白后正庚烷提取 ,反相高效液相法分别测定了大鼠静脉注射利巴韦林单方药和利巴韦林复方粉针剂后的血药浓度并计算其药代动力学参数。结果利巴韦林复方粉针剂在大鼠体内的隔室模型和药代动力学参数与利巴韦林原料药无显著差别 ,t1/2 β分别为 (2 0 7 5 0 3± 38 6 81)min和 (189 35 4± 2 0 4 80 )min ,AUC分别为 (10 5 8 90 0± 2 5 3 2 78)mg·min·L-1和 (1139 5 12± 383 793)mg·min·L-1。
Objective To study on the pharmacokinetics of ribavirin and sodium houttuylfonate compound preparation for injection and comparison with that of ribavirin preparation and inspect the influence of the other components sodium houttuylfonate to the pharmacokinetics parameters of ribavirin.Methods The concentration of ribavirin in plasma of rats after i.v.were determined by the protein sedimentation with 50%(φ) perchloric-extract with n-heptane RP-HPLC method and the plasma concentration-time curves were plotted.The main pharmacokinetic parameters of ribavirin in the compound preparation and ribavirin preparation were obtained.Results The compartment model and the pharmcokinetic parameters of ribavirin in the compound preparation and ribavirin itself have no significant difference.The t 1/2β of ribavirin in the two parameters were (207.503±38.681) min and (189.354±20.480) min,respectively;AUC of those were ( 1 058.900±253.278)mg·min·L -1 and ( 1 139.512±383.793)mg·min·L -1,respectively.Conclusions Sodium houttuylfonate in the compound prepration has no influence to the pharmacokinetics of ribavirin.
出处
《沈阳药科大学学报》
CAS
CSCD
2004年第3期161-164,共4页
Journal of Shenyang Pharmaceutical University
